Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10064561 | 0.88 | ALDH1A1 (0.33) | ALDH1A1TSHRALOX15NPSR1 | |
| SCHEMBL17946111 | 0.88 | ALDH1A1 (0.33) | ALDH1A1ALOX15NPSR1 | |
| SCHEMBL6124306 | 0.84 | ALOX15 (0.32) | ALDH1A1ALOX15NPSR1 | |
| SCHEMBL11543220 | 0.82 | CHRM2 (0.31) | ALDH1A1ALOX15NPSR1 | |
| SCHEMBL22597519 | 0.81 | DNM1 (0.40) | ALDH1A1ALOX15NPSR1 | |
| SCHEMBL4092337 | 0.79 | ADH1A (0.40) | ALOX15 | |
| SCHEMBL20926094 | 0.78 | ALDH1A1 (0.32) | ALDH1A1NPSR1 | |
| SCHEMBL13183386 | 0.78 | — | — | |
| SCHEMBL28397595 | 0.78 | ALOX15 (0.38) | ALOX15 | |
| SCHEMBL10586375 | 0.78 | ALOX15 (0.36) | ALDH1A1ALOX15NPSR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048097-B2 | METHOD FOR PRODUCING AN N-METHYL SUBSTITUTED TRIACETONE AMINE COMPOUND | EVONIK OPERATIONS GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| EP-3048097-B1 | METHOD FOR PRODUCING AN N-METHYL SUBSTITUTED TRIACETONE AMINE COMPOUND | EVONIK DEGUSSA GMBH (DE) | 2019-04-24 | — | — | EP | disclosed |
| US-9617245-B2 | Process for preparing an N-methyl-substituted triacetonamine compound | EVONIK DEGUSSA GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617245-B2 | Process for preparing an N-methyl-substituted triacetonamine compound | EVONIK DEGUSSA GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-20160214962-A1 | PROCESS FOR PREPARING AN N-METHYL-SUBSTITUTED TRIACETONAMINE COMPOUND | EVONIK DEGUSSA GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214962-A1 | PROCESS FOR PREPARING AN N-METHYL-SUBSTITUTED TRIACETONAMINE COMPOUND | EVONIK DEGUSSA GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214962-A1 | PROCESS FOR PREPARING AN N-METHYL-SUBSTITUTED TRIACETONAMINE COMPOUND | HNMT, COMT, PNMT | ALDH1A1 1129/4885TSHR 381/4885ALOX15 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.